Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!
All News
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? This edition: PHOENYCS GO (dapirolizumab pegol in SLE).
Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-T ce
In July 2026, JAMA concisely reviewed the bidirectional relationship between sleep health and obesity. Obesity affects roughly 40% of US adults and sleep problems affect nearly one-third. This review outlines the biological mechanisms and clinical interventions relevant to weight management.
Epidemiologic estimates on systemic lupus erythematosus (SLE) diagnosis are limited.
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.


